Medium-term Effects of Treatments in Autoimmune Encephalitis
A legfontosabb adatok
- Ki végzi
- Hospices Civils de Lyon
- Hol
- Franciaország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 200 fő, tervezett
- Kezdés
- 2024. szept. 1.
- Várható befejezés
- 2027. márc. 1.
- A vizsgálat típusa
- Megfigyeléses, 6 csoport
- A vizsgált kezelések
- We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- A regiszteradat frissítve
- 2025. augusztus 20.
Ki vehet részt
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 3 feltétel megnézéseKevesebb
Ki vehet részt
- Adult or child patient with encephalitis defined as anti-GAD, NMDAR, LGI1, CASPR2, IgLON5 or GFAP
- Untreated or with a decision to treat within the previous 30 days
Ki nem vehet részt
- Refusal by the referring doctor to participate or refusal by the patient mentioned in the objection to the use of his/her clinical data
Ez a vizsgálat jelenleg itt érhető el: Franciaország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence. Commonly used treatments are divided into so-called first-line (steroids, intravenous immunoglobulins, plasma exchanges) and second-line (rituximab, cyclophosphamide, tocilizumab, others), and may be used in association or sequentially. There is no standard practice, and initial treatment protocol may consist in first-line alone, first-line with rituximab, or first-line with dual immunosuppression (rituximab and cyclophosphamide). Absence of clear response to initial treatment in the first 4 to 6 weeks may indicate undertreatment and is generally followed by treatment escalation, mostly to dual immunosuppression. However, as the frequency of non-responders to initial treatment is unknown, it is still unclear whether dual immunosuppression should be offered to all patients from inception.
A vizsgálat 6 csoportja
- group 1 : Patients with NMDAR encephalitis
Patients with untreated anti-NMDAR encephalitis or with a decision to treat within the previous 30 days
Kezelés: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- group 2 : Patients with GAD encephalitis
Patients with untreated anti-GAD encephalitis or with a decision to treat within the previous 30 days
Kezelés: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- group 3 : Patients with LGI1 encephalitis
Patients with untreated anti-LGI1 encephalitis or with a decision to treat within the previous 30 days
Kezelés: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- group 4 : Patients with IgLON5 encephalitis
Patients with untreated anti-IgLON5 encephalitis or with a decision to treat within the previous 30 days
Kezelés: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- group 5 : Patients with GFAP encephalitis
Patients with untreated anti-GFAP encephalitis or with a decision to treat within the previous 30 days
Kezelés: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- group 6 : Patients with CASPR2 encephalitis
Patients with untreated anti-CASPR2 encephalitis or with a decision to treat within the previous 30 days
Kezelés: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Medium-term Effects of Treatments in Autoimmune Encephalitis (META): a Real-life, Observational Prospective Study
- A regiszteradat frissítve
- 2025. augusztus 20.